ClearPoint Neuro (CLPT) Net Income towards Common Stockholders (2011 - 2026)
ClearPoint Neuro (CLPT) posted Net Income towards Common Stockholders of -$9.6 million for Q1 2026, down 23.2% sequentially from -$7.8 million in Q4 2025, and down 58.51% YoY from -$23.0 million in Q1 2025.
ClearPoint Neuro (CLPT) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
ClearPoint Neuro has reported Net Income towards Common Stockholders for 15 years, with the latest figure at -$9.6 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 58.51% year-over-year to -$9.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.0 million (down 44.21% YoY) and the FY2025 annual result came in at -$25.5 million, down 39.75% from the prior year.
- Net Income towards Common Stockholders declined to -$9.6 million in Q1 2026 per CLPT's latest filing, from -$7.8 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$4.1 million in Q1 2024 and troughed at -$14.7 million in Q2 2022.
- A 5-year average of -$7.6 million and a median of -$6.0 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders jumped 62.47% in 2024, then plunged 64.12% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$4.6 million in 2022, then dropped by 5.47% to -$4.9 million in 2023, then advanced by 3.49% to -$4.7 million in 2024, then tumbled by 64.12% to -$7.8 million in 2025, then slipped by 23.2% to -$9.6 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$9.6 million, -$7.8 million, and -$5.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn | 201.00 Mn |
| 10 | ClearPoint Neuro | 466.68 Mn | 437.28 Mn | 6.71 Mn | -11.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.34 Mn |
| Mar 31, 2026 | -9.55 Mn |
| Dec 31, 2025 | -7.75 Mn |
| Sep 30, 2025 | -5.89 Mn |
| Jun 30, 2025 | -5.84 Mn |
| Mar 31, 2025 | -6.03 Mn |
| Dec 31, 2024 | -4.72 Mn |
| Sep 30, 2024 | -4.97 Mn |
| Jun 30, 2024 | -4.41 Mn |
| Mar 31, 2024 | -4.15 Mn |
| Dec 31, 2023 | -4.90 Mn |
| Sep 30, 2023 | -6.76 Mn |
| Jun 30, 2023 | -11.23 Mn |
| Mar 31, 2023 | -11.05 Mn |
| Dec 31, 2022 | -4.64 Mn |
| Sep 30, 2022 | -11.05 Mn |
| Jun 30, 2022 | -14.68 Mn |
| Mar 31, 2022 | -11.36 Mn |
| Dec 31, 2021 | -4.46 Mn |
| Sep 30, 2021 | -19.13 Mn |